Hyaluronic acid nanoparticles for active targeting atherosclerosis

Biomaterials

Volumn 53, Issue , 2015, Pages 341-348

  Lee, Ga Young ^a,b   Kim, Jong Ho ^c   Choi, Ki Young ^d   Yoon, Hong Yeol ^d,e   Kim, Kwangmeyung ^d   Kwon, Ick Chan ^d   Choi, Kuiwon ^d   Lee, Byung Heon ^a   Park, Jae Hyung ^e   Kim, In San ^d,f  

^a Kyungpook National University School of Medicine   (South Korea)

^b Korea National Institute of Health   (South Korea)

^c Kyung Hee University   (South Korea)

^d Korea Institute of Science and Technology   (South Korea)

^e Sungkyunkwan University   (South Korea)

^f Korea University   (South Korea)

Author keywords

Active targeting; Atherosclerosis; Hyaluronic acid; Nanoparticles

Indexed keywords

DISEASES; MAMMALS; MOLECULAR BIOLOGY; NANOPARTICLES; ORGANIC ACIDS;

ACTIVE TARGETING; ATHEROSCLEROSIS; ATHEROSCLEROTIC LESIONS; ATHEROSCLEROTIC PLAQUE; IMMUNOHISTOCHEMISTRY; OPTICAL IMAGING SYSTEM; RECEPTOR-MEDIATED ENDOCYTOSIS; SYSTEMIC ADMINISTRATION;

HYALURONIC ACID;

APOLIPOPROTEIN E; DRUG CARRIER; HERMES ANTIGEN; HYALURONIC ACID; HYALURONIC ACID NANOPARTICLE; NANOPARTICLE; RECEPTOR; STABILIN 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; ENDOCYTOSIS; FEMALE; FLUORESCENCE IMAGING; GENE OVEREXPRESSION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; ANIMAL; C57BL MOUSE; CELL LINE; CHEMISTRY; HUMAN;

ANIMALIA; MUS;

ANIMALS; ATHEROSCLEROSIS; CELL LINE; HUMANS; HYALURONIC ACID; MICE; MICE, INBRED C57BL; NANOPARTICLES;

EID: 84927915334     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.02.089     Document Type: Article

References (36)

1. Weber C., Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011, 17:1410-1422.
2. Lindsay A.C., Choudhury R.P. Form to function: current and future roles for atherosclerosis imaging in drug development. Nat Rev Drug Discov 2008, 7:517-529.
3. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
4. Choudhury R.P., Fuster V., Fayad Z.A. Molecular, cellular and functional imaging of atherothrombosis. Nat Rev Drug Discov 2004, 3:913-925.
5. Virmani R., Kolodgie F.D., Burke A.P., Farb A., Schwartz S.M. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000, 20:1262-1275.
6. Davies M.J. Anatomic features in victims of sudden coronary death. Coronary artery pathology. Circulation 1992, 85:I19-I24.
7. Navab M., Shechter I., Anantharamaiah G.M., Reddy S.T., Van Lenten B.J., Fogelman A.M. Structure and function of HDL mimetics. Arterioscler Thromb Vasc Biol 2010, 30:164-168.
8. Serruys P.W., Garcia-Garcia H.M., Buszman P., Erne P., Verheye S., Aschermann M., et al. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008, 118:1172-1182.
9. Klingenberg R., Hansson G.K. Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. Eur Heart J 2009, 30:2838-2844.
10. Lobatto M.E., Fuster V., Fayad Z.A., Mulder W.J. Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat Rev Drug Discov 2011, 10:835-852.
11. You D.G., Saravanakumar G., Son S., Han H.S., Heo R., Kim K., et al. Dextran sulfate-coated superparamagnetic iron oxide nanoparticles as a contrast agent for atherosclerosis imaging. Carbohydr Polym 2014, 101:1225-1233.
12. Lee G.Y., Kim J.H., Oh G.T., Lee B.H., Kwon I.C., Kim I.S. Molecular targeting of atherosclerotic plaques by a stabilin-2-specific peptide ligand. JControl Release 2011, 155:211-217.
13. Luehmann H.P., Pressly E.D., Detering L., Wang C., Pierce R., Woodard P.K., et al. PET/CT imaging of chemokine receptor CCR5 in vascular injury model using targeted nanoparticle. JNucl Med 2014, 55:629-634.
14. Hinterwirth H., Stubiger G., Lindner W., Lammerhofer M. Gold nanoparticle-conjugated anti-oxidized low-density lipoprotein antibodies for targeted lipidomics of oxidative stress biomarkers. Anal Chem 2013, 85:8376-8384.
15. Pan H., Myerson J.W., Hu L., Marsh J.N., Hou K., Scott M.J., et al. Programmable nanoparticle functionalization for invivo targeting. FASEB J 2013, 27:255-264.
16. Lapcik L., Lapcik L., De Smedt S., Demeester J., Hyaluronan Chabrecek P. Preparation, structure, properties, and applications. Chem Rev 1998, 98:2663-2684.
17. Platt V.M., Szoka F.C. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharmacol 2008, 5:474-486.
18. Choi K.Y., Saravanakumar G., Park J.H., Park K. Hyaluronic acid-based nanocarriers for intracellular targeting: interfacial interactions with proteins in cancer. Colloids Surf B Biointerfaces 2012, 99:82-94.
19. Yoon H.Y., Kim H.R., Saravanakumar G., Heo R., Chae S.Y., Um W., et al. Bioreducible hyaluronic acid conjugates as siRNA carrier for tumor targeting. JControl Release 2013, 172:653-661.
20. Han H.S., Lee J., Kim H.R., Chae S.Y., Kim M., Saravanakumar G., et al. Robust PEGylated hyaluronic acid nanoparticles as the carrier of doxorubicin: mineralization and its effect on tumor targetability invivo. JControl Release 2013, 168:105-114.
21. Yoon H.Y., Koo H., Choi K.Y., Chan Kwon I., Choi K., Park J.H., et al. Photo-crosslinked hyaluronic acid nanoparticles with improved stability for invivo tumor-targeted drug delivery. Biomaterials 2013, 34:5273-5280.
22. Choi K.Y., Jeon E.J., Yoon H.Y., Lee B.S., Na J.H., Min K.H., et al. Theranostic nanoparticles based on PEGylated hyaluronic acid for the diagnosis, therapy and monitoring of colon cancer. Biomaterials 2012, 33:6186-6193.
23. Choi K.Y., Yoon H.Y., Kim J.H., Bae S.M., Park R.W., Kang Y.M., et al. Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy. ACS Nano 2011, 5:8591-8599.
24. Bot P.T., Hoefer I.E., Piek J.J., Pasterkamp G. Hyaluronic acid: targeting immune modulatory components of the extracellular matrix in atherosclerosis. Curr Med Chem 2008, 15:786-791.
25. Hägg D., Sjöberg S., Hultén L.M., Fagerberg B., Wiklund O., Rosengren A., et al. Augmented levels of CD44 in macrophages from atherosclerotic subjects: a possible IL-6-CD44 feedback loop?. Atherosclerosis 2007, 190:291-297.
26. Krettek A., Sukhova G.K., Schonbeck U., Libby P. Enhanced expression of CD44 variants in human atheroma and abdominal aortic aneurysm: possible role for a feedback loop in endothelial cells. Am J Pathol 2004, 165:1571-1581.
27. Kamat M., El-Boubbou K., Zhu D.C., Lansdell T., Lu X., Li W., et al. Hyaluronic acid immobilized magnetic nanoparticles for active targeting and imaging of macrophages. Bioconjug Chem 2010, 21:2128-2135.
28. Choi K.Y., Chung H., Min K.H., Yoon H.Y., Kim K., Park J.H., et al. Self-assembled hyaluronic acid nanoparticles for active tumor targeting. Biomaterials 2010, 31:106-114.
29. Park J.H., Kwon S., Lee M., Chung H., Kim J.H., Kim Y.S., et al. Self-assembled nanoparticles based on glycol chitosan bearing hydrophobic moieties as carriers for doxorubicin: invivo biodistribution and anti-tumor activity. Biomaterials 2006, 27:119-126.
30. Kim K., Kim J.H., Park H., Kim Y.S., Park K., Nam H., et al. Tumor-homing multifunctional nanoparticles for cancer theragnosis: simultaneous diagnosis, drug delivery, and therapeutic monitoring. JControl Release 2010, 146:219-227.
31. Park S.Y., Jung M.Y., Kim H.J., Lee S.J., Kim S.Y., Lee B.H., et al. Rapid cell corpse clearance by stabilin-2, a membrane phosphatidylserine receptor. Cell Death Differ 2008, 15:192-201.
32. Park K., Hong H.Y., Moon H.J., Lee B.H., Kim I.S., Kwon I.C., et al. Anew atherosclerotic lesion probe based on hydrophobically modified chitosan nanoparticles functionalized by the atherosclerotic plaque targeted peptides. JControl Release 2008, 128:217-223.
33. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat Rev Drug Discov 2007, 6:273-286.
34. Schroeder A., Heller D.A., Winslow M.M., Dahlman J.E., Pratt G.W., Langer R., et al. Treating metastatic cancer with nanotechnology. Nat Rev Cancer 2012, 12:39-50.
35. Bourzac K. Nanotechnology: carrying drugs. Nature 2012, 491:S58-S60.
36. Petros R.A., DeSimone J.M. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010, 9:615-627.